1. Home
  2. Expression of surface and intracellular specific markers by human stem cells derived from Lipostem™-treated adipose tissue - Lipogems

Expression of surface and intracellular specific markers by human stem cells derived from Lipostem™-treated adipose tissue - Lipogems

A Raspa, S Carelli, F Messaggio, G Marfia…

Abstract

Background: The antiproliferative effects of immunosuppressive drugs such as sirolimus and tacrolimus used in human islet transplantation interfere with the capacity of β cells to balance cell renewal and cell loss. This feature may be an important contributor to progressive graft dysfunction in islet transplant recipients over time. We analyzed the influence of different immunosuppressants on ɑ and β cell proliferation and transplant outcome following syngeneic β cell transplantation in mice. Methods: Syngeneic islets (300 IP) were injected into the right liver lobes of C57BL/6 diabetic recipients. Osmotic pumps filled with bromodeoxyuridine (BrdU)(control) or BrdU and an immunosuppressant [tacrolimus, sirolimus, everolimus, or mycophenolate mofetil (MMF)] were implanted. Glycemic control was assessed using glucose tolerance tests. After four weeks, proliferation of ɑ and β cells was detected by BrdU incorporation. In addition, fractional β cell area and average β cell size was determined by morphometric analysis. Results: The average blood glucose levels were significantly higher in all treatment groups compared to controls. Glucose tolerance was improved only in control animals (P 0.009). The fractional β cell area and β cell proliferation in MMF-treated mice were comparable to control mice (P= 0.66). In contrast, treatment with everolimus and sirolimus led to a significant reduction in β cell proliferation and fractional β cell area. While transplanted β cells from animals treated with tacrolimus also presented a reduced replication rate (P= 0.023), the fractional β cell area was not affected compared to untreated controls (P= 0.72). Conclusions: Our …

View Publication

Attention

The information available on the website istitutoimage.it is intended solely for informational purposes and is in no way a substitute for specialist medical advice. The contents are drafted in compliance with Art. 56 of the FNOMCeO Code of Ethics and the Ministerial Circular dated 18/12/2024. The information published has been prepared by qualified doctors and surgeons and is solely for educational purposes:

  • it does not in any way constitute a diagnosis;
  • it does not replace the direct doctor-patient relationship;
  • it must not be used as a prescription for treatments or as a basis for autonomous therapeutic decisions.

To assess suitability for aesthetic medicine treatments or plastic surgery procedures, a specialist medical consultation is always required.

For any questions, the Image Regenerative Clinic team is available with no obligation. Read the full Disclaimer.

Mission

This website is aimed at users seeking qualified and up-to-date information about regenerative aesthetic medicine, plastic surgery and longevity programs. Its contents are intended to provide general knowledge and are not a substitute for the doctor-patient relationship. Image Regenerative Clinic is committed to offering scientifically supported treatments and therapies with the utmost transparency and in full compliance with current regulations.

Website Authors

Dr. Carlo Tremolada – OMCEO Milan registration no. 30098  All the contents and images on this website have been written, reviewed and approved by the internal Medical-Scientific Committee coordinated by Dr. Carlo Tremolada, in compliance with Art. 56 of the FNOMCeO Code of Ethics and current regulations on healthcare advertising.

Website Ownership

The website istitutoimage.it is owned by Image Regenerative Clinic S.r.l.

It does not contain banner advertising, does not host sponsored content and does not benefit from grants or revenue from external advertising.